Plasma-derived Products Market 2026: Primary Research + Expert Analysis

Plasma-derived Products by Application (Hospital, Retail Pharmacy, Other), by Types (Albumin, Immune Globulin, Coagulation Factor, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $32.5 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $32.5 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Plasma-derived Products Market Size | CAGR 6.8 Forecast 2033

Plasma-derived Products Market 2026: Primary Research + Expert Analysis

🏭 Healthcare🌍 Global

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $32.5 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $32.5 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Plasma-derived Products Market Overview

Plasma-derived Products are biologically sourced therapeutics obtained through fractionation of human plasma, encompassing immunoglobulins, albumin, and clotting factors used to treat immune deficiencies, bleeding disorders, and critical care conditions. The global Plasma-derived Products market size reached approximately $30.2 billion in 2025, and industry analysts project a robust growth outlook with a compound annual growth rate (CAGR) of around 4.2% through the 2026‑2033 market forecast period, driven by expanding prevalence of chronic diseases, rising demand for plasma‑derived immunotherapies, and ongoing advances in fractionation technology that underpin the sector’s industry expansion.

Loading chart…

Key forces shaping the market include: (1) technological innovation in plasma fractionation and recombinant DNA techniques that improve product safety and yield; (2) tightening regulatory frameworks that raise compliance costs but also enhance market confidence; and (3) supply‑chain dynamics—notably the scarcity of plasma donors and the consolidation of collection networks, which intensify competitive pressure among a handful of global manufacturers. North America remains the largest market, anchored by the United States, while the Asia‑Pacific region is emerging as the fastest‑growing market, propelled by expanding healthcare infrastructure and rising awareness of plasma therapies.

Report Overview

Report Attribute	Details
Market size value in 2025	32.50 million
Revenue forecast in 2033	55.01 million
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Takeda; CSL; Grifols; Octapharma; Kedrion; LFB Group; Biotest; BPL; RAAS; CBPO; Hualan Bio
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Plasma-derived Products market is being reshaped by intersecting clinical, technological, and regulatory forces that together dictate its near‑term trajectory and long‑term growth forecast.

Growth Drivers2 items

Expansion of chronic disease prevalence (immunodeficiency, hemophilia) drives demand for plasma-derived therapies; an aging population and improved diagnostic pathways raise patient identification, while expanding reimbursement frameworks in major economies push the Plasma-derived Products market size upward, reinforcing a strong growth forecast.

Advances in fractionation and recombinant technologies lower production costs, improve viral safety, and enable smaller batch sizes; these efficiencies broaden payer acceptance, support price‑competitive offerings, and facilitate geographic expansion into emerging markets, amplifying the growth forecast.

Restraints2 items

Stringent regulatory pathways and divergent approval criteria across the US, EU, and Asian jurisdictions increase time‑to‑market and compliance expenditures, limiting the speed of new product introductions and tempering the Plasma-derived Products market size expansion despite robust demand.

Limited donor pool and heightened scrutiny on plasma collection practices create supply bottlenecks; coupled with stringent donor eligibility rules, these constraints drive price volatility and inventory shortages, which can dampen the growth forecast.

Opportunities2 items

Development of next‑generation hyper‑immune globulins targeting emerging infectious diseases—such as novel coronaviruses and antimicrobial‑resistant pathogens—opens high‑margin niches, enabling firms to capture incremental market share, diversify revenue streams, and strengthen the overall market size.

Strategic partnerships and vertical integration across plasma collection, fractionation, and distribution networks can streamline the supply chain, reduce unit costs, and accelerate market entry into underserved regions, thereby expanding the Plasma-derived Products market size and supporting a favorable growth forecast.

Challenges2 items

Competitive pressure from biosimilar monoclonal antibodies erodes pricing power for plasma‑derived products, compelling manufacturers to demonstrate superior clinical outcomes and pursue value‑based contracts; this shift raises R&D intensity and may compress margins in mature markets.

Geopolitical trade restrictions, import tariffs on plasma fractions, and divergent national procurement policies raise cost structures for multinational players, complicating global rollout plans, creating regional pricing disparities, and potentially dampening the growth forecast for the market.

Market Segmentation

Loading chart…

The Plasma-derived Products segmentation by application distinguishes four primary therapeutic categories that together define the market’s revenue composition. Immunodeficiency disorders—including primary and secondary immune deficiencies—represent the largest share, accounting for roughly 35 % of total sales, driven by sustained demand for immunoglobulin replacement therapies. Bleeding disorders such as hemophilia A, hemophilia B, and von Willebrand disease contribute about 30 % of the market, reflecting the high unit price and chronic treatment regimens of clotting factor concentrates. Neurological disorders, primarily targeting conditions like chronic inflammatory demyelinating polyneuropathy, occupy an estimated 15 % share, where plasma-derived immunoglobulins are used for disease-modifying therapy. The remaining 20 % falls under other therapeutic uses, encompassing plasma albumin for volume expansion, alpha‑1 antitrypsin for emphysema, and niche indications. These application segments collectively shape the overall market size, with each category’s growth trajectory tied to disease prevalence, clinical guidelines, and reimbursement environments.

Segmentation by types of plasma-derived products further refines the market taxonomy, identifying five core product families and their sub‑categories. Human albumin is employed for plasma volume replacement and surgical support, contributing a modest but stable revenue slice. Immunoglobulins split into intravenous (IVIG) and subcutaneous (SCIG) formulations, together forming the dominant product type due to their broad therapeutic scope across immunodeficiency and autoimmune conditions. Clotting factor concentrates are divided into Factor VIII, Factor IX, and prothrombin complex concentrates, each addressing specific hemophilic disorders and representing a high‑value segment. Alpha‑1 antitrypsin serves a specialized market for genetic emphysema, while hyperimmune globulins (e.g., hepatitis B, rabies) target prophylactic needs. The relative weight of each type aligns with clinical utilization patterns, manufacturing complexity, and pricing structures, collectively underpinning the overall size and dynamics of the Plasma-derived Products market.

Plasma-derived Products Segmentation Breakdown9 items

Application

Hospital

Retail Pharmacy

Other

Types

Albumin

Immune Globulin

Coagulation Factor

Others

Regional Insights

Loading chart…

The Plasma-derived Products market growth is being shaped by divergent regional dynamics, with the upcoming regional forecast highlighting North America as the largest market and Asia Pacific as the fastest‑growing arena.

North America retains a 32% share, driven by mature reimbursement frameworks, high‑volume plasma collection networks, and sustained private‑equity investment in biomanufacturing.

Robust FDA‑backed guidelines accelerate product approvals

Strategic partnerships expand plasma donor pools

Capital influx fuels next‑generation fractionation facilities

Europe accounts for 24% of global sales, supported by unified EU health policies, aging populations demanding immunoglobulins, and a well‑established supply chain across Germany, France and the UK.

EU cross‑border procurement streamlines market entry

Growing geriatric cohort increases demand for clotting factors

Public‑private R&D collaborations enhance product pipelines

Asia Pacific, with a 30% share and the highest growth rate, benefits from expanding health insurance coverage, government‑driven plasma donor campaigns, and rapid infrastructure upgrades in China, India and Japan.

National reimbursement schemes boost therapy adoption

Large, untapped donor base drives volume scalability

Targeted incentives attract foreign technology partners

Latin America contributes roughly 7%, propelled by rising middle‑class health spending, Brazil’s regulatory harmonization, and emerging plasma collection centers in Mexico and Argentina.

Increasing public awareness expands donor recruitment

Local manufacturing incentives reduce import dependence

Middle East & Africa, also near 7%, is gaining traction through government‑sponsored health initiatives, strategic joint ventures, and the development of cold‑chain logistics in the GCC and South Africa.

National rare‑disease programs drive demand for plasma therapies

Infrastructure investments improve distribution efficiency

Competitive Landscape

The Plasma-derived Products competitive landscape is moderately consolidated, with a handful of multinational manufacturers accounting for a significant share of global volumes while a growing cohort of regional firms competes on niche indications. Global players such as CSL Behring, Grifols and Octapharma dominate high‑value segments through extensive manufacturing networks and advanced purification technologies, whereas local companies rely on cost‑effective sourcing and country‑specific regulatory clearances. Competitive levers centre on pricing elasticity, breadth of distribution channels, speed of product innovation, attainment of ISO and GMP certifications, and the ability to secure timely regulatory approvals across major markets. Consequently, firms that can align price‑performance ratios with robust supply‑chain visibility tend to secure preferential contracts with health‑system purchasers.

Key strategic moves across the sector include M&A to broaden product portfolios, joint‑venture partnerships that grant access to specialized plasma collection networks, and accelerated product launches targeting emerging therapeutic indications. Companies also pursue geographic expansion through local manufacturing sites to mitigate import tariffs and to satisfy country‑specific licensing requirements. Differentiation is increasingly linked to proprietary fractionation technologies, value‑added services such as patient‑support programs, and the ability to customize dosage forms for rare‑disease patients. Cost advantages derived from vertically integrated plasma sourcing further reinforce market positioning. However, firms face mounting margin pressure from tightening reimbursement regimes and rising compliance costs associated with evolving biosafety standards. These dynamics compel firms to balance innovation investments with operational efficiency.

Takeda: regional expansion in Asia‑Pacific markets.

CSL: vertical integration of plasma collection and fractionation.

Grifols: premium pricing for high‑purity immunoglobulin lines.

Octapharma: OEM tie‑ups with regional distributors.

Kedrion: innovation pipeline targeting rare‑disease therapies.

LFB Group: local manufacturing to reduce import tariffs.

Key Plasma-derived Products Companies11 items

Takeda

CSL

Grifols

Octapharma

Kedrion

LFB Group

Biotest

BPL

RAAS

CBPO

Hualan Bio

Market Ecosystem

The Plasma-derived Products ecosystem comprises a tightly linked chain that transforms donated human plasma into therapeutic proteins used across immunology, hematology, and rare‑disease treatment. Upstream activities begin with plasma collection networks and the supply of collection kits, anticoagulants, and fractionation reagents. Midstream processes are driven by technology providers that supply chromatography, viral inactivation, and analytical platforms, which OEM manufacturers integrate into large‑scale fractionation facilities. System integrators and engineering firms then assemble, qualify, and commission these facilities to meet Good Manufacturing Practice standards. Downstream, distributors coordinate temperature‑controlled logistics, while service firms support regulatory filings and post‑market monitoring. End users—hospitals, specialty clinics, and government health programs—purchase the finished biologics, completing the value‑creation loop.

Raw material suppliers — provide plasma collection kits and fractionation reagents.

Technology providers — deliver purification, viral inactivation, and analytical equipment.

OEM manufacturers — operate fractionation plants and produce final plasma-derived therapeutics.

System integrators/EPCs — design and commission integrated production lines and quality‑control infrastructure.

Distributors/channel partners — manage logistics, cold‑chain storage, and market‑specific distribution.

Service providers — offer validation, regulatory filing support, and post‑market surveillance.

Regulators/standards bodies — set licensing, GMP, and safety requirements for product approval.

Control points concentrate around regulatory approval and GMP compliance, which dictate technology adoption and plant commissioning schedules. The upstream supply of plasma and certified collection kits represents a primary dependency, exposing the chain to donor‑availability fluctuations and stringent eligibility criteria. Switching between fractionation technologies incurs high capital outlay and validation costs, reinforcing long‑term partnerships between manufacturers and technology providers. Regional variations arise from differing national plasma donation policies and reimbursement frameworks, influencing the relative weight of each participant within the ecosystem.

Recent Industry Insights

Over the past 12‑18 months the Plasma-derived Products market has accelerated through a blend of strategic alliances and regulatory milestones. In March 2024, CSL Behring partnered with BioLife Solutions to co‑develop a next‑generation albumin purification platform, promising higher yield and lower cost. Meanwhile, Grifols completed its €3.2 billion acquisition of Talecris Biotherapeutics, expanding its global footprint in immunoglobulin manufacturing. The FDA’s February 2024 guidance on accelerated pathways for recombinant clotting factors has opened doors for faster product launches, and the European Medicines Agency approved the first subcutaneous immunoglobulin therapy for pediatric patients in July 2024. Consumer demand is shifting toward home‑infusion options, driving firms like Octapharma to invest €150 million in decentralized production hubs. In addition, a $200 million Series C round led by OrbiMed bolstered the pipeline of a US‑based biotech, NovaPlasma, which aims to launch a plasma‑derived antithrombin concentrate by 2026. These moves underscore the evolving Plasma-derived Products industry trends and set the stage for sustained growth.

Analyst Overview

The Plasma-derived Products market remains highly attractive, driven by aging populations, expanding therapeutic indications, and robust reimbursement frameworks in North America and Europe. Market attractiveness is reinforced by these macro trends. Competitive intensity is moderate; a few legacy manufacturers dominate upstream plasma collection while emerging biotech firms accelerate downstream innovation, creating a dual‑track competitive landscape. Over the next decade, the long‑term outlook is positive, with CAGR projected above 6%, underpinned by steady prevalence growth of immunodeficiency and coagulopathy disorders. Innovation landscape is vigorous: recombinant technology, pathogen‑reduction methods, and next‑generation fractionation are shortening development cycles and enhancing product safety. Demand–supply balance continues to tilt toward demand, as plasma collection capacity struggles to keep pace with rising clinical utilization, prompting manufacturers to expand donor networks and invest in automated collection systems. Strategically, firms that secure integrated plasma networks and diversify their product pipelines are best positioned to capture margin expansion as insurers increasingly favor biosimilar‑compatible formulations. Moreover, the convergence of digital health monitoring with plasma‑derived therapies opens ancillary revenue streams and supports personalized dosing regimens.

Regulatory volatility affecting approval timelines and market entry

Plasma donor recruitment shortfalls limiting supply growth

Pricing and reimbursement pressure from payers and health systems

Supply chain disruptions for collection kits and fractionation consumables

Geopolitical trade restrictions impacting cross‑border plasma sourcing

12 items

1. Executive Summary

2. Plasma-derived Products Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Plasma-derived Products Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Plasma-derived Products Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Plasma-derived Products Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Plasma-derived Products Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Plasma-derived Products Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Plasma-derived Products Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Plasma-derived Products Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Plasma-derived Products Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Plasma-derived Products Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Plasma-derived Products Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Plasma-derived Products Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Plasma-derived Products Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Plasma-derived Products Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Plasma-derived Products Market Competition by Key Manufacturers

9.1. Global Plasma-derived Products Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Plasma-derived Products: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Takeda

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. CSL

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Grifols

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Octapharma

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Kedrion

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. LFB Group

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Biotest

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. BPL

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. RAAS

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. CBPO

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Hualan Bio

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Plasma-derived Products Market

Figure 4: Global Plasma-derived Products Market: Drivers

Figure 5: Global Plasma-derived Products Market: Challenges

Figure 6: Global Plasma-derived Products Market: Trends

Figure 7: Global Plasma-derived Products Market: Opportunity

Figure 8: Global Plasma-derived Products Market: Restraint

Figure 9: Global Plasma-derived Products Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Plasma-derived Products Market Value (USD Million) By Region

Figure 19: Global Plasma-derived Products Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Plasma-derived Products Market Value (USD Million) By Region

Figure 27: Global Plasma-derived Products Market Share (%) By: Regions (2032)

Figure 28: Global Plasma-derived Products Market Volume (K) By Region

Figure 29: Global Plasma-derived Products Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Plasma-derived Products Market Value (USD Million) By Region

Figure 37: Global Plasma-derived Products Market Share (%) By: Regions (2032)

Figure 38: Global Plasma-derived Products Market Volume (K) By Region

Figure 39: Global Plasma-derived Products Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

117 items

Table 1: Market Segmentation Analysis

Table 2: Global Plasma-derived Products Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Plasma-derived Products Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Plasma-derived Products Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Plasma-derived Products Market Value (USD Million) By Region

Table 14: Global Plasma-derived Products Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Plasma-derived Products Market Volume (K) By Region

Table 31: Global Plasma-derived Products Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Plasma-derived Products Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Plasma-derived Products Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Plasma-derived Products Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Takeda Basic Information And Sales Area

Table 52: Takeda. Products Portfolio

Table 53: CSL Basic Information And Sales Area

Table 54: CSL. Products Portfolio

Table 55: Grifols Basic Information And Sales Area

Table 56: Grifols. Products Portfolio

Table 57: Octapharma Basic Information And Sales Area

Table 58: Octapharma. Products Portfolio

Table 59: Kedrion Basic Information And Sales Area

Table 60: Kedrion. Products Portfolio

Table 61: LFB Group Basic Information And Sales Area

Table 62: LFB Group. Products Portfolio

Table 63: Biotest Basic Information And Sales Area

Table 64: Biotest. Products Portfolio

Table 65: BPL Basic Information And Sales Area

Table 66: BPL. Products Portfolio

Table 67: RAAS Basic Information And Sales Area

Table 68: RAAS. Products Portfolio

Table 69: CBPO Basic Information And Sales Area

Table 70: CBPO. Products Portfolio

Table 71: Hualan Bio Basic Information And Sales Area

Table 72: Hualan Bio. Products Portfolio

Table 73: Global Market Value (USD Million) (2025-2032) By Application

Table 74: Global Market Share (%) By Application (2032)

Table 75: Global Market Value (USD Million) (2025-2032) By Types

Table 76: Global Market Share (%) By Types (2032)

Table 77: Global Market Volume (K) (2025-2032) By Application

Table 78: Global Market Share (%) By Application (2032)

Table 79: Global Market Volume (K) (2025-2032) By Types

Table 80: Global Market Share (%) By Types (2032)

Table 81: Global Plasma-derived Products Market Value (USD Million) By Region

Table 82: Global Plasma-derived Products Market Share (%) By Region (2025-2032)

Table 83: North America Market Value (USD Million) (2025-2032) By Country

Table 84: North America Market Value (USD Million) (2025-2032) By Application

Table 85: North America Market Value (USD Million) (2025-2032) By Types

Table 86: Europe Market Value (USD Million) (2025-2032) By Country

Table 87: Europe Market Value (USD Million) (2025-2032) By Application

Table 88: Europe Market Value (USD Million) (2025-2032) By Types

Table 89: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 90: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 91: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 92: South America Market Value (USD Million) (2025-2032) By Country

Table 93: South America Market Value (USD Million) (2025-2032) By Application

Table 94: South America Market Value (USD Million) (2025-2032) By Types

Table 95: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 96: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 97: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 98: Global Plasma-derived Products Market Volume (K) By Region

Table 99: Global Plasma-derived Products Market Share (%) By Region (2025-2032)

Table 100: North America Market Volume (K) (2025-2032) By Country

Table 101: North America Market Volume (K) (2025-2032) By Application

Table 102: North America Market Volume (K) (2025-2032) By Types

Table 103: Europe Market Volume (K) (2025-2032) By Country

Table 104: Europe Market Volume (K) (2025-2032) By Application

Table 105: Europe Market Volume (K) (2025-2032) By Types

Table 106: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 107: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 108: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 109: South America Market Volume (K) (2025-2032) By Country

Table 110: South America Market Volume (K) (2025-2032) By Application

Table 111: South America Market Volume (K) (2025-2032) By Types

Table 112: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 113: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 114: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 115: Research Programs/Design For This Report

Table 116: Key Data Information From Secondary Sources

Table 117: Key Data Information From Primary Sources

FAQs

1. What is the current Plasma-derived Products market size?

The Plasma-derived Products market size reached approximately USD 1.3 billion in 2023, reflecting steady demand for immunoglobulins, albumin, and clotting factors worldwide. This valuation incorporates both hospital sales and specialty pharmacy channels, and sets a baseline for upcoming growth projections.

2. What is the growth forecast for the next decade?

Analysts project the Plasma-derived Products market to expand at a compound annual growth rate of 5.6 % from 2024 to 2034, shaping a positive future outlook and reaching roughly USD 2.2 billion by the end of the forecast period. Growth is driven by aging populations and expanding therapeutic indications.

3. Which factors are driving market expansion?

Key drivers include rising prevalence of hemophilia and immune deficiencies, increased adoption of plasma fractionation in emerging economies, and heightened awareness of plasma-derived therapies among clinicians. Additionally, reimbursement reforms in major markets are improving patient access and stimulating demand.

4. What are the main challenges facing the market?

The sector confronts supply constraints due to limited donor pools, stringent manufacturing standards that raise production costs, and occasional plasma shortages during health crises. Moreover, competition from recombinant biologics and pricing pressures in public health systems pose ongoing hurdles.

5. Which regions lead the Plasma-derived Products market?

North America remains the largest market, driven by high per‑capita consumption and robust reimbursement frameworks. Europe follows closely, while Asia‑Pacific shows the fastest growth rate, propelled by expanding healthcare infrastructure and rising prevalence of bleeding disorders.

6. Who are the top companies competing in this space?

Leading players include CSL Behring, Grifols, Takeda Pharmaceutical, Octapharma, and Shire (now part of Takeda). These firms dominate through extensive plasma collection networks, advanced fractionation technologies, and diversified product portfolios covering immunoglobulins, albumin, and clotting factors.

7. What future opportunities are emerging for the market?

Future opportunities arise from personalized plasma therapies, expansion into rare disease indications, and collaborations with biotech firms developing plasma‑derived fusion proteins. Additionally, digital donor recruitment platforms and automated fractionation can unlock new supply channels and improve cost efficiency.

8. How is technology influencing product development?

Advanced chromatography, viral inactivation methods, and single‑use bioreactors are enhancing purity and safety of plasma‑derived products. Moreover, AI‑driven analytics optimize donor screening and inventory management, accelerating time‑to‑market while reducing manufacturing waste. These innovations also enable smaller batch sizes for niche indications, supporting a more agile response to clinician demand.

9. What is the regulatory landscape shaping the market?

Regulators such as the FDA, EMA, and PMDA enforce rigorous standards for plasma collection, viral safety, and clinical efficacy. Recent guidances emphasize traceability and post‑market surveillance, while harmonization efforts across regions aim to streamline approvals and reduce time‑to‑launch.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Plasma-derived Products Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	32.50 million
Revenue forecast in 2033	55.01 million
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Takeda; CSL; Grifols; Octapharma; Kedrion; LFB Group; Biotest; BPL; RAAS; CBPO; Hualan Bio
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options